{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T10:33:08Z","timestamp":1787567588188,"version":"build-2736575974"},"reference-count":97,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nutrients"],"abstract":"<jats:p>Substance use disorders (SUDs) remain a major public health concern and contribute substantially to compromised quality of life, mortality, and healthcare burden. In the United States alone, millions of individuals are affected by alcohol use disorder (AUD), tobacco use disorder (TUD), and opioid use disorder (OUD), with many cases complicated by co-existing anxiety and stress-related disorders. Piper methysticum G. Forst (kava), a traditional South Pacific plant preparation, has gained attention for its anxiolytic, sedative, and sleep-promoting properties. Its pharmacological effects are primarily attributed to a set of lipophilic compounds known as kavalactones, which have been reported to modulate GABAA receptor activity, dopaminergic and adrenergic signaling pathways, monoamine oxidase-B activity, cannabinoid receptor type 1 activity, and voltage-gated ion channels. Peer-reviewed literature was identified through searches of PubMed, NIH resources, and other scientific databases using terms related to kava, kavalactones, addiction, anxiety, stress, insomnia, and SUDs. Both clinical and preclinical studies were reviewed, including investigations of neurotransmitter systems and addiction-related signaling pathways. The current literature suggests that the strongest rationale for kava use exists in AUD, where anxiety and stress are established contributors to relapse. Evidence supporting kava use in TUD and OUD is largely theoretical, while concerns regarding hepatotoxicity, cytochrome P450 interactions, product variability, and additive risk remain important barriers to its clinical application. In summary, current evidence does not support kava as a replacement for established therapies, while its unique pharmacological profile warrants further investigation as a potential adjunctive treatment for withdrawal and relapse in SUDs.<\/jats:p>","DOI":"10.3390\/nu18172747","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T09:20:02Z","timestamp":1787563202000},"page":"2747","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Kava (Piper methysticum G. Forst) for Substance Use Disorders: A Review of Mechanism, Pharmacology, Clinical Evidence, and Therapeutic Potential"],"prefix":"10.3390","volume":"18","author":[{"given":"Jason","family":"Krehl","sequence":"first","affiliation":[{"name":"Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL 32611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2879-129X","authenticated-orcid":false,"given":"Jessica Nissi","family":"Mamallapalli","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL 32611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4266-6236","authenticated-orcid":false,"given":"Chengguo","family":"Xing","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL 32611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2302-8949","authenticated-orcid":false,"given":"Oliver","family":"Grundmann","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL 32611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,22]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2024). Global Status Report on Alcohol and Health and Treatment of Substance Use Disorders, World Health Organization."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jhep.2013.03.007","article-title":"Global burden of alcoholic liver diseases","volume":"59","author":"Rehm","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_3","unstructured":"U.S. Department of Health and Human Services (2014). The Health Consequences of Smoking\u201450 Years of Progress: A Report of the Surgeon General."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41380-020-0661-4","article-title":"The changing opioid crisis: Development, challenges and opportunities","volume":"26","author":"Volkow","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/nrn3110","article-title":"Pharmacogenetic approaches to the treatment of alcohol addiction","volume":"12","author":"Heilig","year":"2011","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1001\/jama.2013.283787","article-title":"Pharmacological treatments for smoking cessation","volume":"311","author":"Cahill","year":"2014","journal-title":"JAMA"},{"key":"ref_7","first-page":"CD002207","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2014","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_8","unstructured":"Administration SA and MHS (2021). TIP 63: Medications for Opioid Use Disorder."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"122","DOI":"10.7326\/ANNALS-24-02318","article-title":"Opportunities for innovation in smoking cessation therapies: A perspective from the National Institutes of Health and US Food and Drug Administration","volume":"178","author":"Warraich","year":"2025","journal-title":"Ann. Intern. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"720","DOI":"10.7326\/M21-4011","article-title":"The management of substance use disorders: Synopsis of the 2021 US Department of Veterans Affairs and US Department of Defense clinical practice guideline","volume":"175","author":"Perry","year":"2022","journal-title":"Ann. Intern. Med."},{"key":"ref_11","unstructured":"WFO (2026, August 17). Piper methysticum G. Forst. World Flora Online. Available online: http:\/\/www.worldfloraonline.org\/taxon\/wfo-0000486456."},{"key":"ref_12","unstructured":"Vincent, L., Mark, M., and Lamont, L. (1997). Kava: The Pacific Elixir: The Definitive Guide to Its Ethnobotany, History, and Chemistry, Healing Arts Press."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1016\/S0024-3205(02)01555-2","article-title":"Kava-kava and anxiety: Growing knowledge about the efficacy and safety","volume":"70","author":"Bilia","year":"2002","journal-title":"Life Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1111\/dar.14080","article-title":"Global Perspectives on Kava: A Narrative Systematic Review of the Health Effects, Economic and Social Impacts and Policy Considerations","volume":"44","author":"Economidis","year":"2025","journal-title":"Drug Alcohol Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1600-0773.1992.tb00530.x","article-title":"Kava pyrones and resin: Studies on GABAA, GABAB and benzodiazepine binding sites in rodent brain","volume":"71","author":"Davies","year":"1992","journal-title":"Pharmacol. Toxicol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/BF02247480","article-title":"Kavapyrone enriched extract from Piper methysticum as modulator of the GABA binding site in different regions of rat brain","volume":"116","author":"Jussofie","year":"1994","journal-title":"Psychopharmacology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1055\/a-1008-9491","article-title":"Monoamine oxidase inhibition by kavalactones from kava (Piper methysticum)","volume":"85","author":"Prinsloo","year":"2019","journal-title":"Planta Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1046\/j.1440-1614.2002.01027.x","article-title":"The neurobehavioural effects of kava","volume":"36","author":"Cairney","year":"2002","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0924-977X(98)00008-X","article-title":"Effects of (\u00b1)-kavain on voltage-activated inward currents of dorsal root ganglion cells from neonatal rats","volume":"9","author":"Schirrmacher","year":"1999","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.phrs.2012.04.003","article-title":"Kavalactones and the endocannabinoid system: The plant-derived yangonin is a novel CB1 receptor ligand","volume":"66","author":"Ligresti","year":"2012","journal-title":"Pharmacol. Res."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Bian, T., Corral, P., Wang, Y., Botello, J., Kingston, R., Daniels, T., Salloum, R.G., Johnston, E., Huo, Z., and Lu, J. (2020). Kava as a Clinical Nutrient: Promises and Challenges. Nutrients, 12.","DOI":"10.3390\/nu12103044"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S1521-6918(03)00031-3","article-title":"Alcohol addiction research: From animal models to clinics","volume":"17","author":"Spanagel","year":"2003","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"386","DOI":"10.35946\/arcr.v34.4.02","article-title":"Overview: Stress and alcohol use disorders revisited","volume":"34","author":"Anthenelli","year":"2012","journal-title":"Alcohol. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S2215-0366(16)00104-8","article-title":"Neurobiology of addiction: A neurocircuitry analysis","volume":"3","author":"Koob","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"ref_25","unstructured":"World Health Organization (2007). Assessment of the Risk of Hepatotoxicity with Kava Products, WHO Regional Office Europe."},{"key":"ref_26","first-page":"1","article-title":"An Introduction to Kava Piper methysticum","volume":"Volume 37","author":"Singh","year":"2004","journal-title":"Kava: From Ethnology to Pharmacology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"115514","DOI":"10.1016\/j.jep.2022.115514","article-title":"Clinical pharmacokinetics of kavalactones after oral dosing of standardized kava extract in healthy volunteers","volume":"297","author":"Kanumuri","year":"2022","journal-title":"J. Ethnopharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Wang, Y., Eans, S.O., Stacy, H.M., Narayanapillai, S.C., Sharma, A., Fujioka, N., Haddad, L., McLaughlin, J., Avery, B.A., and Xing, C. (2018). A stable isotope dilution tandem mass spectrometry method of major kavalactones and its applications. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0197940"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1055\/s-2001-14334","article-title":"Interaction of various Piper methysticum cultivars with CNS receptors in vitro","volume":"67","author":"Dinh","year":"2001","journal-title":"Planta Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/jps.2600771203","article-title":"Uptake into mouse brain of four compounds present in the psychoactive beverage kava","volume":"77","author":"Keledjian","year":"1988","journal-title":"J. Pharm. Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1365-2710.2007.00810.x","article-title":"Permeability studies of Kavalactones using a Caco-2 cell monolayer model","volume":"32","author":"Matthias","year":"2007","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Chua, H.C., Christensen, E.T.H., Hoestgaard-Jensen, K., Hartiadi, L.Y., Ramzan, I., Jensen, A.A., Absalom, N.L., and Chebib, M. (2016). Kavain, the major constituent of the anxiolytic kava extract, potentiates GABAA receptors: Functional characteristics and molecular mechanism. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0157700"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s002130100686","article-title":"Anxiolytic effects of kava extract and kavalactones in the chick social separation-stress paradigm","volume":"155","author":"Smith","year":"2001","journal-title":"Psychopharmacology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/ptr.1107","article-title":"Anxiolytic properties of Piper methysticum extract samples and fractions in the chick social\u2013separation\u2013stress procedure","volume":"17","author":"Feltenstein","year":"2003","journal-title":"Phytother. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1124\/dmd.30.11.1153","article-title":"Inhibition of human cytochrome P450 activities by kava extract and kavalactones","volume":"30","author":"Mathews","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.toxlet.2003.07.005","article-title":"Kava kava: Examining new reports of toxicity","volume":"150","author":"Clouatre","year":"2004","journal-title":"Toxicol. Lett."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1021\/tx020113r","article-title":"Identification of novel electrophilic metabolites of Piper methysticum Forst. (Kava)","volume":"16","author":"Johnson","year":"2003","journal-title":"Chem. Res. Toxicol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1001\/jama.2010.1689","article-title":"Risk of kava hepatotoxicity and the FDA consumer advisory","volume":"304","author":"Teschke","year":"2010","journal-title":"JAMA"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1665-2681(19)31634-5","article-title":"Kava hepatotoxicity. A clinical review","volume":"9","author":"Teschke","year":"2010","journal-title":"Ann. Hepatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.dld.2011.01.018","article-title":"Herbal hepatotoxicity by kava: Update on pipermethystine, flavokavain B, and mould hepatotoxins as primarily assumed culprits","volume":"43","author":"Teschke","year":"2011","journal-title":"Dig. Liver Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"100215","DOI":"10.1016\/j.dmd.2025.100215","article-title":"Inhibition of cytochrome P450 2B6 activity by dihydromethysticin: Structural and mechanistic insights","volume":"54","author":"Wang","year":"2025","journal-title":"Drug Metab. Dispos."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"152260","DOI":"10.1016\/j.aanat.2024.152260","article-title":"Pharmacological effects of methysticin and L-sulforaphane through the Nrf2\/ARE signaling pathway in MLO-Y4 osteocytes: In vitro study","volume":"254","author":"Dittmar","year":"2024","journal-title":"Ann. Anat.-Anat. Anz."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.redox.2017.04.024","article-title":"Oral administration of methysticin improves cognitive deficits in a mouse model of Alzheimer\u2019s disease","volume":"12","author":"Fragoulis","year":"2017","journal-title":"Redox Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1124\/mol.107.042499","article-title":"Kavalactones protect neural cells against amyloid \u03b2 peptide-induced neurotoxicity via extracellular signal-regulated kinase 1\/2-dependent nuclear factor erythroid 2-related factor 2 activation","volume":"73","author":"Wruck","year":"2008","journal-title":"Mol. Pharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1196\/annals.1441.030","article-title":"Chronic stress, drug use, and vulnerability to addiction","volume":"1141","author":"Sinha","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_46","first-page":"103","article-title":"Brain dopamine and reward","volume":"1","author":"Wise","year":"1981","journal-title":"Theory Psychopharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"469","DOI":"10.34172\/apb.2024.036","article-title":"Kavain alleviates choroidal neovascularization via decreasing the activity of the HIF-1\u03b1\/VEGF-A\/VEGFR2 signaling pathway and inhibiting inflammation","volume":"14","author":"Chen","year":"2024","journal-title":"Adv. Pharm. Bull."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1055\/s-2002-36338","article-title":"Kavalactones and dihydrokavain modulate GABAergic activity in a rat gastric-brainstem preparation","volume":"68","author":"Yuan","year":"2002","journal-title":"Planta Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1055\/s-2006-957502","article-title":"Influence of genuine kavapyrone enantiomers on the GABAA binding site","volume":"64","author":"Boonen","year":"1998","journal-title":"Planta Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.bcp.2005.12.032","article-title":"Inhibition of TNF\u03b1-induced activation of nuclear factor \u03baB by kava (Piper methysticum) derivatives","volume":"71","author":"Folmer","year":"2006","journal-title":"Biochem. Pharmacol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/ptr.3695","article-title":"Kavalactone metabolism in rat liver microsomes","volume":"26","author":"Fu","year":"2012","journal-title":"Phytother. Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1078\/0944-7113-00068","article-title":"Cyclooxygenase enzyme inhibitory compounds with antioxidant activities from Piper methysticum (kava kava) roots","volume":"9","author":"Wu","year":"2002","journal-title":"Phytomedicine"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"118394","DOI":"10.1016\/j.jep.2024.118394","article-title":"Yangonin, one of the kavalactones isolated from Piper methysticum G. Forst, acts through cannabinoid 1 (CB1) receptors to induce an intrathecal anti-hyperalgesia","volume":"333","author":"Chow","year":"2024","journal-title":"J. Ethnopharmacol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1055\/s-2007-979325","article-title":"Inhibition of platelet MAO-B by kava pyrone-enriched extract from Piper methysticum Forster (kava-kava)","volume":"31","author":"Uebelhack","year":"1998","journal-title":"Pharmacopsychiatry"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00213-009-1549-9","article-title":"The Kava Anxiety Depression Spectrum Study (KADSS): A randomized, placebo-controlled crossover trial using an aqueous extract of Piper methysticum","volume":"205","author":"Sarris","year":"2009","journal-title":"Psychopharmacology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1177\/0004867419891246","article-title":"Kava for generalised anxiety disorder: A 16-week double-blind, randomised, placebo-controlled study","volume":"54","author":"Sarris","year":"2020","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/00004850-200207000-00005","article-title":"A placebo-controlled study of Kava kava in generalized anxiety disorder","volume":"17","author":"Connor","year":"2002","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/00004850-200609000-00001","article-title":"Kava in generalized anxiety disorder: Three placebo-controlled trials","volume":"21","author":"Connor","year":"2006","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"5897","DOI":"10.1002\/ptr.7999","article-title":"Effect of kava (Piper methysticum) on peripheral gene expression among individuals with generalized anxiety disorder: A post hoc analysis of a randomized controlled trial","volume":"37","author":"Cribb","year":"2023","journal-title":"Phytother. Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1078\/1433-187X-00309","article-title":"Kava-Kava extract LI 150 is as effective as Opipramol and Buspirone in Generalised Anxiety Disorder\u2013an 8-week randomized, double-blind multi-centre clinical trial in 129 out-patients","volume":"10","author":"Boerner","year":"2003","journal-title":"Phytomedicine"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/JCP.0b013e318291be67","article-title":"Kava in the treatment of generalized anxiety disorder: A double-blind, randomized, placebo-controlled study","volume":"33","author":"Sarris","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_62","first-page":"CD003383","article-title":"Kava extract versus placebo for treating anxiety","volume":"2003","author":"Pittler","year":"2003","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1055\/a-1708-1994","article-title":"Characterization of different forms of kava (Piper methysticum) products by UPLC-MS\/MS","volume":"88","author":"Mamallapalli","year":"2022","journal-title":"Planta Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jemermed.2023.01.010","article-title":"Emergency department management of patients with alcohol intoxication, alcohol withdrawal, and alcohol use disorder: A white paper prepared for the American Academy of Emergency Medicine","volume":"64","author":"Strayer","year":"2023","journal-title":"J. Emerg. Med."},{"key":"ref_65","first-page":"43","article-title":"The spectrum of alcohol use: Epidemiology, diagnosis, and treatment","volume":"106","author":"Cohen","year":"2022","journal-title":"Med. Clin."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1001\/jama.2022.4308","article-title":"Alcohol-related deaths during the COVID-19 pandemic","volume":"327","author":"White","year":"2022","journal-title":"JAMA"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.15585\/mmwr.mm6939a6","article-title":"Deaths and years of potential life lost from excessive alcohol use\u2014United States, 2011\u20132015","volume":"69","author":"Esser","year":"2020","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.15585\/mmwr.mm7144a5","article-title":"Quickstats: Age-adjusted rates* of alcohol-induced deaths, \u2020 by urban-rural status \u00a7\u2014United States, 2000\u20132020","volume":"71","author":"Spencer","year":"2022","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1001\/archneur.64.11.1575","article-title":"Dopamine in drug abuse and addiction: Results of imaging studies and treatment implications","volume":"64","author":"Volkow","year":"2007","journal-title":"Arch. Neurol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1080\/10615806.2025.2571524","article-title":"Family history of alcohol use disorder and stress-reactivity","volume":"39","author":"Armeli","year":"2026","journal-title":"Anxiety Stress Coping"},{"key":"ref_71","first-page":"117","article-title":"Naltrexone treatment improves anxiety-and depression-like behavior in alcohol-exposed mice","volume":"37","author":"Yang","year":"2026","journal-title":"Behav. Pharmacol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"103060","DOI":"10.1016\/j.janxdis.2025.103060","article-title":"Prevalence and correlates of alcohol, cannabis, and tobacco use disorder in DSM-5 generalized anxiety disorder: Findings from the National Epidemiologic Survey on Alcohol and Related Conditions-III","volume":"115","author":"Zech","year":"2025","journal-title":"J. Anxiety Disord."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00213-025-06752-8","article-title":"Influence of real-world cue exposure and mood states on drinking: Testing neurobiological models of alcohol use disorder","volume":"242","author":"Meredith","year":"2025","journal-title":"Psychopharmacology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"pyaf056","DOI":"10.1093\/ijnp\/pyaf056","article-title":"Antidepressant efficacy of ketamine plus naltrexone for major depression comorbid with alcohol use disorder: A randomized controlled trial","volume":"28","author":"Yoon","year":"2025","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.neuropharm.2017.05.023","article-title":"Sex-and hormone-dependent alterations in alcohol withdrawal-induced anxiety and corticolimbic endocannabinoid signaling","volume":"124","author":"Henricks","year":"2017","journal-title":"Neuropharmacology"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"fcaa123","DOI":"10.1093\/braincomms\/fcaa123","article-title":"The effect of alcohol withdrawal syndrome severity on sleep, brain and cognition","volume":"2","author":"Laniepce","year":"2020","journal-title":"Brain Commun."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Shen, G., Chen, Y.-H., Wu, Y., Jiahui, H., Fang, J., Jiayi, T., Yimin, K., Wang, W., Liu, Y., and Wang, F. (2024). Exploring core symptoms of alcohol withdrawal syndrome in alcohol use disorder patients: A network analysis approach. Front. Psychiatry, 15.","DOI":"10.3389\/fpsyt.2024.1320248"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13011-026-00728-3","article-title":"Kava (Piper methysticum) consumption patterns and conceptualizations: Results from an online survey","volume":"21","author":"Hill","year":"2026","journal-title":"Subst. Abus. Treat. Prev. Policy"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/00952990.2022.2140292","article-title":"Kava (Piper methysticum) in the United States: The quiet rise of a substance with often subtle effects","volume":"49","author":"Kheyfets","year":"2023","journal-title":"Am. J. Drug Alcohol Abus."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e041011","DOI":"10.1136\/bmjopen-2020-041011","article-title":"Smoking cessation interventions for people living in rural and remote areas: A systematic review protocol","volume":"10","author":"Lum","year":"2020","journal-title":"BMJ Open"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1177\/0193945919828061","article-title":"Disparities in rural tobacco use, smoke-free policies, and tobacco taxes","volume":"41","author":"Miller","year":"2019","journal-title":"West J. Nurs. Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1093\/ntr\/ntad246","article-title":"Smoking quit attempts and associated factors among rural adults who smoke daily in the United States","volume":"26","author":"Bittencourt","year":"2024","journal-title":"Nicotine Tob. Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"475","DOI":"10.15585\/mmwr.mm7218a1","article-title":"Tobacco product use among adults\u2013United States, 2021","volume":"72","author":"Cornelius","year":"2023","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.15585\/mmwr.mm6744a2","article-title":"Tobacco product use among adults\u2014United States, 2017","volume":"67","author":"Wang","year":"2018","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.15585\/mmwr.mm7244a1","article-title":"Tobacco product use among US middle and high school students\u2014National Youth Tobacco Survey, 2023","volume":"72","author":"Birdsey","year":"2023","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.amepre.2014.10.012","article-title":"Annual healthcare spending attributable to cigarette smoking: An update","volume":"48","author":"Xu","year":"2015","journal-title":"Am. J. Prev. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e834","DOI":"10.1016\/S2468-2667(22)00202-X","article-title":"Economic loss attributable to cigarette smoking in the USA: An economic modelling study","volume":"7","author":"Nargis","year":"2022","journal-title":"Lancet Public Health"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"120617","DOI":"10.1016\/j.jep.2025.120617","article-title":"Prevalence and use patterns of kava (Piper methysticum) in a US nationally representative sample","volume":"355","author":"Mamallapalli","year":"2025","journal-title":"J. Ethnopharmacol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1021\/acsptsci.4c00415","article-title":"Flavokavains A-and B-Free Kava Enhances Resilience against the Adverse Health Effects of Tobacco Smoke in Mice","volume":"7","author":"Bian","year":"2024","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"100940","DOI":"10.1016\/j.phyplu.2025.100940","article-title":"AB-Free Kava Suppresses Tobacco Smoke-Induced CREB Phosphorylation in the Mouse Cerebellum","volume":"6","author":"Wang","year":"2025","journal-title":"Phytomed. Plus"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Xing, C., Malaty, J., Malham, M.B., Orlando, F.A., Lynch, A., Huo, Z., Fran\u00e7ois, M., Firpi-Morell, R., Fisher, C.L., and Christou, D.D. (2024). The potential of AB-free kava in enabling tobacco cessation via management of abstinence-related stress and insomnia: Study protocol for a randomized clinical trial. BMC Complement Med. Ther., 24.","DOI":"10.1186\/s12906-024-04722-9"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13011-020-00308-z","article-title":"Recent changes in trends of opioid overdose deaths in North America","volume":"15","author":"Imtiaz","year":"2020","journal-title":"Subst. Abus. Treat. Prev. Policy"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"108350","DOI":"10.1016\/j.drugalcdep.2020.108350","article-title":"The economic burden of opioid use disorder and fatal opioid overdose in the United States, 2017","volume":"218","author":"Florence","year":"2021","journal-title":"Drug Alcohol Depend."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2165\/00002018-200225040-00003","article-title":"A systematic review of the safety of kava extract in the treatment of anxiety","volume":"25","author":"Stevinson","year":"2002","journal-title":"Drug Saf."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jep.2004.04.009","article-title":"Pharmacokinetic and pharmacodynamic drug interactions with Kava (Piper methysticum Forst. f.)","volume":"93","author":"Anke","year":"2004","journal-title":"J. Ethnopharmacol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.clpt.2005.01.009","article-title":"In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4\/5 phenotypes","volume":"77","author":"Gurley","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/j.fct.2011.06.075","article-title":"Proposal for a kava quality standardization code","volume":"49","author":"Teschke","year":"2011","journal-title":"Food Chem. Toxicol."}],"container-title":["Nutrients"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6643\/18\/17\/2747\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T09:27:10Z","timestamp":1787563630000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6643\/18\/17\/2747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,22]]},"references-count":97,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["nu18172747"],"URL":"https:\/\/doi.org\/10.3390\/nu18172747","relation":{},"ISSN":["2072-6643"],"issn-type":[{"value":"2072-6643","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,22]]}}}